What is EPI-Q?
EPI-Q operates as a specialized consultancy at the intersection of clinical research and health economics. The firm provides comprehensive services that synthesize real-world evidence (RWE) to validate the safety and economic value of medical products throughout their entire life cycle. By employing a multidisciplinary team of clinicians, methodologists, and health economists, EPI-Q addresses the complex requirements of healthcare systems and providers.
The company's core competency lies in its ability to translate intricate clinical data into actionable insights that satisfy the evolving demands of global regulatory bodies and reimbursement authorities. As the healthcare industry shifts toward value-based care models, EPI-Q remains a critical partner for organizations seeking to demonstrate product efficacy and cost-effectiveness in competitive markets.
How much funding has EPI-Q raised?
EPI-Q has raised a total of $305K across 2 funding rounds:
Debt
$150K
Debt
$155K
Debt (2020): $150K with participation from PPP
Debt (2021): $155K led by PPP
Key Investors in EPI-Q
PPP
Public-Private Partnership
What's next for EPI-Q?
With the successful closure of this latest financing round, EPI-Q is poised to scale its service offerings and deepen its technological infrastructure. The strategic deployment of this capital will likely focus on enhancing the firm's proprietary methodologies for evidence generation, ensuring that clients can navigate the increasingly stringent requirements of global healthcare systems.
Looking ahead, the company is expected to further solidify its market leadership by expanding its footprint in emerging markets where the demand for rigorous health economic analysis is rising. By continuing to bridge the gap between clinical outcomes and economic value, EPI-Q is set to remain an indispensable asset for stakeholders navigating the complexities of modern pharmaceutical and medical device commercialization.
